TDP-43-positive inclusions are present in the amygdala in frontotemporal lobar degeneration (FTLD) and motor neuron disease (MND) including amyotrophic lateral sclerosis. Behavioral abnormalities, one of the chief symptoms of FTLD, could be, at least partly, related to amygdala pathology. We examined TDP-43 inclusions in the amygdala of patients with sporadic FTLD/MND (sFTLD/MND), FTLD/MND with mutation of the C9ORF72 (FTLD/MND-C9) and FTLD with mutation of the progranulin (FTLD-GRN). TDP-43 inclusions were common in each one of these subtypes, which can otherwise be distinguished on topographical and genetic grounds. Conventional and immunological stainings were performed and we quantified the numerical density of inclusions on a regional basis. TDP-43 inclusions in amygdala could be seen in 10 out of 26 sFTLD/MND cases, 5 out of 9 FTLD/MND-C9 cases, and all 4 FTLD-GRN cases. Their numerical density was lower in FTLD/MND-C9 than in sFTLD/MND and FTLD-GRN. TDP-43 inclusions were more numerous in the ventral region of the basolateral nucleus group in all subtypes. This contrast was apparent in sporadic and C9-mutated FTLD/MND, while it was less evident in FTLD-GRN. Such differences in subregional involvement of amygdala may be related to the region-specific neuronal connections that are differentially affected in FTLD/MND and FTLD-GRN.
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is clinically and pathologically heterogeneous, and comprises 2 main groups: tau-positive and tau-negative FTLD (1) . The major form of tau-negative FTLD is associated with neuronal inclusions composed of TAR DNA-binding protein 43 (TDP-43) (2, 3) . It is characterized by neuronal loss and gliosis associated with TDP-43-positive inclusions in neurons of the frontotemporal neocortices, limbic regions (such as the insular cortex, hippocampus, and amygdala), and some subcortical nuclei (4, 5) . This disease group, the so-called FTLD-TDP, is pathologically and genetically classified into further subtypes: (1) sporadic FTLD with motor neuron disease (sFTLD/MND); (2) FTLD/MND with mutation of the C9ORF72 gene (FTLD/ MND-C9); (3) FTLD with mutation of the progranulin gene (FTLD-GRN); and (4) FTLD with other mutations (6) (7) (8) (9) . The involvement of the amygdala is incriminated in such symptoms as emotional impairments or behavior disturbance (10, 11) , commonly occurring in these diseases (12) . However, it remains unclear whether the distribution and severity of TDP-43 pathology in the amygdala is different between these subtypes of FTLD-TDP.
In this study, we plotted and counted TDP-43-positive inclusions in the amygdala in the representative subtypes of FTLD-TDP: sFTLD/MND, FTLD/MND-C9, and FTLD-GRN. We analyzed their topography, density and their relationship with neuronal loss and tau accumulation. We found that the distribution of TDP-43-positive inclusions was different in these 3 subtypes and their development was different from that of tau accumulation. These differences in regional distribution and density may provide an anatomo-pathological basis for clinical differentiation of these subtypes.
MATERIALS AND METHODS

Cases
Informed consent for autopsy and genetic analysis was obtained in all cases from the patient himself prospectively or from the patient's family. Among all the cases which were analyzed postmortem in the Raymond Escourolle neuropathology laboratory of the Pitié-Salpêtrière Hospital from 1998 to 2013, there were 26 sporadic MND cases with or without frontotemporal dementia (sFTLD/MND), including 18 males and 8 females with mean age of 65.3 years 6 8.2 years (standard deviation), in whom no mutation in SOD1, C9ORF72, TARDBP, and FUS genes had been identified, 9 MND cases (6 male, 3 female) with hexanucleotide expansion in C9ORF72 (FTLD/MND-C9) (56.4 6 7.7 years) and 4 FTLD cases (3 male, 1 female) with mutation in the GRN gene encoding the progranulin (FTLD-GRN) (70.8 6 6.3 years). All of the cases of MND harbored TDP-43-positive skein-like/ rounded inclusions in the motor neuron of the spinal cord and/ or of the hypoglossal nuclei.
Tissue Preparation and Immunohistochemistry
The amygdala, hippocampus, medulla oblongata, inferior temporal, and anterior frontal cortices and spinal cord were fixed in formalin for at least 2 months. Three-lm-thick sections of paraffin-embedded tissue were stained with haematein and eosin (H&E). The amygdala and hippocampus were immunostained for phosphorylated TDP-43 (polyclonal, pS409/410, 1: 5000, CosmoBio, Tokyo, Japan) (13) , nonphosphorylated TDP-43 (polyclonal, 10782-2AP, 1:1000, ProteinTech, Chicago, IL) (3), AT8 (monoclonal, AT8, 1:500, ThermoScientific, Waltham, MA) (14) , amyloid b (monoclonal, 6F/3D, 1:200, Dako, Glostrup, Denmark) (Ab) (15), asynuclein (monoclonal, KM51, 1:10, Novocastra, Newcastle, UK) (16) , and p62 (monoclonal, 3/p62 LCK ligand, 1:500, BD Biosciences, Franklin Lakes, NJ) (17) . The immunostaining of phosphorylated TDP-43, nonphosphorylated TDP-43, AT8, asynuclein and p62 was performed by an automatic slides stainer (Benchmark XT Ventana staining systems, Tucson, AZ). The slides were pretreated at 95 C in CC1 (pH 8) proprietary retrieval buffer (Ventana Medical Systems, Tucson, AZ) for 8 minutes. In addition to CC1 incubation, slides were pretreated by formic acid for 5 minutes and proteinase K for 32 minutes when immunostained with the a-synuclein antibody. Immunohistochemistry for Ab was manually performed. The slides were pretreated by formic acid for 10 minutes, and were incubated overnight with 6F/3D antibody. The biotinylated secondary antibody was detected by the ABC method coupled with a diaminobenzidine (DAB) reaction. The streptavidin-biotinylated peroxidase complex (ABC) was revealed with DAB.
Anatomical Identification of the Amygdaloid Nuclei
The brain was serially cut; the sections were 1 cm apart. The amygdala was sampled in the slice in which the amygdala had the largest extent so that both the corticomedial and basolateral subgroups could be identified.
The amygdala was divided into 2 large groups: corticomedial group (CMG) and basolateral group (BLG) (Fig. 1A) . The CMG is further subdivided into medial nucleus (Me), periamygdaloid complex (PAC) and temporal piriform cortex (PC), and the BLG is further subdivided into lateral nucleus (La), basolateral nucleus (BL), basomedial nucleus (BM), and paralaminar nucleus (PL) (Fig. 1A) . In addition, the entorhinal region (EnR) composed of 2 subregions, the entorhinal cortex (EC) and transentorhinal cortex (TEC), can be identified in the same section (18, 19) . The BLG was divided into BLG-dorsal (BLG-D) and BLG-ventral (BLG-V) as shown in Figure 1B by a horizontal line located at mid-distance of the shortest line joining the upper and lower borders of the amygdala (Fig. 1B) . The BLG-D contained a large part of the BL and BM, while the BLG-V included a large part of the La and PL.
Microscopic Pathology
A high-resolution image (0.23 lm/pixel) of a specimen up to 26 Â 76 mm (1.13 Â 10 5 Â 3.30 Â 10 5 pixels) was obtained with a light field scanning microscopy (Nanozoomer Digital Pathology, version 2.5.85, Hamamatsu, Japan) and recorded as digital data. The lesions could be perfectly identified in the digital picture with the suitable magnification (i.e. up to Â1000). The outline of each region of interest (anatomical border of the BLG, CMG and EnR) was traced manually; TDP-43-positive inclusions were plotted and counted in each of the brain maps at Â200 magnification (Fig. 2) . The largest dimension of 10 randomly selected profiles of TDP-43-positive inclusions was measured in each case. The numerical density of the profiles of TDP-43-positive cytoplasmic inclusions was calculated in the CMG, BLG (BLG-D, BLG-V), and EnR. TDP-43-positive dot/neuritic inclusions were exempted from the calculation of its numerical density. We also examined TDP-43-positive inclusions in some frontotemporal regions that are anatomically and functionally connected with amygdala: the dentate gyrus, inferior temporal gyrus, orbital gyrus, inferior frontal cortex, and anterior cingulate gyrus. TDP-43-positive inclusions were semiquantitatively rated into 4 stages (none [À], mild [þ], moderate [ þþ] , and severe [ þþþ]) in these areas. Numerical density of the profiles of p62-positive inclusions was also calculated in the BLG and compared with the profiles of TDP-43-positive inclusions. To compare the densities of TDP-43-positive inclusions in 2 subgroups (between the BLG-V and the other regions), a ratio of their local values was computed. The amygdaloid and entorhinal degeneration was semiquantitatively rated for their severity into 4 grades as follows: normal (0); mild (1, gliosis); moderate (2, gliosis with mild spongiotic changes); and severe (3, severe gliosis and neuronal loss) (Fig. 3A-D) . Three regions of interest (a region size: 0.1 mm 2 ) were randomly chosen in the BLG-V (as a representative of amygdala lesions); the packing density of neurons and astrocytes were quantitatively calculated. The PHF-tau-positive (AT-8-positive) neuronal inclusions including neurofibrillary tangles (NFT) (Fig. 3E-H) were also plotted and counted in each of the maps in cases with TDP-43-positive inclusions.
The numerical packing density of the profile of tau-positive neurons was calculated in the CMG, BLG, and EnR. NFT distribution was staged according to Braak (20, 21) . The distribution of Ab-positive deposits (core of the senile plaque, diffuse deposits) was assessed according to Thal et al. (22) . We also evaluated Ab deposition in the subiculum and CA4 because according to Thal et al. (22) , the packing density of the subicular plaques might be correlated with that of striatum plaques (Thal phase 3) and the packing density of CA4 might be related to that of the midbrain (Thal phase 4). Lewy pathology was assessed after a-synuclein immunohistochemistry and argyrophilic grains were assessed after tau (AT8) immunohistochemistry (23, 24) . A TDP-43 pathologic type was assigned to each case according to the harmonized classification system (25) . In order to evaluate the regional differences of the inclusions density (TDP-43 and tau) along the antero-posterior axis, each section was classified into 3 levels; anterior (the level of anterior commissure), middle (the level of the lateral ventricle), and posterior (the level of the pes hippocampi).
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki declaration and its later amendments ethical standards.
Statistical Analyses
Statistical analyses were performed with the statistical program Ekuseru-Toukei 2012 (Social Survey Research Information Co., Ltd., Tokyo, Japan) and Microsoft Excel (Microsoft Corporation, Redmond, WA). Due to the small sample size, Kruskal-Wallis analysis of variance on ranks or MannWhitney t-test was performed on quantitative and semiquantitative measures. The comparison of the size of the inclusions was performed with one-way ANOVA and post hoc Scheffe's multicomparison test. The Fisher exact test or Chi-square test was used to compare proportions between groups of cases. Spearman rank correlation was used to test correlation. For all tests, the criterion for significance was a probability of type I error p < 0.05.
RESULTS
Clinicopathological Profile
TDP-43 pathology was found in 10/26 (38.5%) cases of sFTLD/MND, 5/9 (55.5%) cases of FTLD/MND-C9 cases and 4/4 (100%) cases FTLD-GRN (Tables 1 and 2 ). In general, patients with amygdala TDP-43 pathology had a higher prevalence of dementia (13 cases with dementia out of 19 cases with amygdala pathology ¼ 68.4%) than those without amygdala TDP-43 pathology (2 cases with dementia out of 20 cases without amygdala pathology ¼ 10.0%; Fisher exact test; p < 0.001) ( Table 2 ). Association of dementia to TDP-43 pathology in amygdala was significant only in sFTLD/MND (6 cases with dementia out of 10 cases with inclusions ¼ 60.0% to be compared to 1 case with dementia out of 16 cases without inclusions ¼ 6.3%; Fisher exact test; p ¼ 0.005, Table 2 ), while it was not significant in the FTLD/MND-C9 and the numbers were too low in the FTLD-GRN group. In our series, we could not compare the degree and quality of dementia in patients with TDP-43 pathology in the amygdala with that in patients without the pathology because of the lack of clinical information in some patients. Brain weights, NFT Braak stage, amyloid Thal phase, Lewy body pathology and argyrophilic grains pathology did not show significant differences between patients with amygdala TDP-43 pathology and without TDP-43 pathology ( 
TDP-43 Cytopathology of Amygdala Lesions
Many of TDP-43-positive neuronal cytoplasmic inclusions were preferentially present in small-sized neurons in all regions, and were mostly well-defined in appearance with the majority being perinuclear curved, cap-like or rounded in shape (Fig. 3I-N, T) (26) . There was no quantitative difference in the size of the cytoplasmic inclusions between sFTLD/ MND, FTLD/MND-C9, and FTLD-GRN (sFTLD/MND: 11.3 6 1.1 lm (mean diameter 6 standard deviation), FTLD/ MND-C9: 11.5 6 1.5 lm and FTLD-GRN: 10.7 6 0.6 lm) ( Table 3) . We thus considered that we could compare the J numerical density of the profiles of the inclusions on the slide in the 3 groups without incurring the risk of having the results distorted by the effect of the size of the inclusions. The neuropil pathology was limited to few dot-like TDP-43-positive neurites in sFTLD/MND (Fig. 3Q) . Some TDP-43-positive dots and threads were found in FTLD/MND-C9 cases (Fig. 3R) . Finally, more abundant dot-like neurites and threads were present in FTLD-GRN cases (Fig. 3S) . TDP-43-positive intranuclear inclusions were not found in sFTLD/MND patients. They were rarely found in FTLD/MND-C9 cases (Fig. 3O ) and were more frequently but still occasionally found in FTLD-GRN cases (Fig. 3P) . FTLD-TDP pathology recognized in cases of sFTLD/MND and FTLD/MND-C9 was of Mackenzie type B in all cases (25) , and was of Mackenzie type A in all cases of FTLD-GRN (Table 1 ) (25).
TDP-43 Distribution and (Semi-)Quantification of Amygdala and Its Associated Lesions
TDP-43-positive inclusions involved all regions especially in the most severely affected patients (Fig. 2) . The results are summarized in Table 3 and show that the mean den- (Tables 3, 4) , especially in the La nucleus (Fig. 3I ) and in the PL nucleus (Fig. 3J) . The value of the ratio (regional density compared with that of BLG-V) was significantly higher in FTLD-GRN than in sFTLD/MND and FTLD/ MND-C9 (Table 3) ; this indicated a more homogeneous distribution in FTLD-GRN (Fig. 4) . To test the possibility that p62 inclusions were in excess of TDP-43 inclusions (as in the cerebellar granule cells for patients carrying C9ORF72 mutations) we compared the densities of TDP-43 and p62-positive inclusions in BLG where they were abundant and present in all cases (12, 27, 28) . There was no significant difference in their packing density (Fig. 5) . TDP-43-positive inclusions extended to the other frontotemporal regions. The total density of amygdaloid TDP-43 inclusions was correlated with the degree of TDP-43 pathology in these areas except orbital gyrus (Supplementary Data Table S1 ).
In all regions of interest (CMG, BLG-D, BLG-V, and EnR), the density of TDP-43-positive inclusions were wellcorrelated with gliosis and neuronal loss. Gliosis and neuronal loss were correlated with tau pathology only in BLG-V (Table  5 ). Gliosis and neuronal loss in the whole amygdala were more severe in FTLD-GRN (2 [0-3]) than in FTLD/MND-C9 (0.5 [0-2]) (Chi-square ¼ 11.99; df ¼ 2; p ¼ 0.003) (Table 3) . Especially, numerical density of TDP-43-positive inclusions was more correlated with packing density of astrocytes (r s ¼ 0.031; n ¼ 19; p ¼ 0.031) than that of neurons (Supplementary Data Table S2 ). In severely affected area, as demonstrated in the entorhinal cortex of case 19, the TDP-43-positive inclusions were rare because of severe neuronal loss. On the other hand, we could identify mild gliosis and neuronal loss in areas with only few TDP-43-positive inclusions, especially in the La or the PAC either because some other processes contributed to neuronal death or because of secondary degeneration related to severe involvement of connected regions ( Fig. 2 ; Cases 1 and 2).
Tau Distribution and (Semi-)Quantification
Tau inclusion pathology in the whole amygdala was significantly more severe in FTLD-GRN than in sFTLD/MND when the comparison between the 3 subtypes was made nucleus by nucleus (Chi-square ¼ 18.86; df ¼ 2; p < 0.001) and FTLD/MND-C9 (Chi-square ¼ 12.76; df ¼ 2; p ¼ 0.002) ( Table 3) . This difference could be possibly explained by the mean age of the patients: In the whole population of cases there was indeed clear correlation between Braak stage and age (r s ¼ 0.561; n ¼ 39; p < 0.001) (Supplementary Data Table S3 ). Equation of the regression analysis showed that Braak stage ¼ 0.087 Â age À 3.63. Using this equation, we found that the Braak stage in each of 3 subgroups was essentially predicted by age rather than by the pathology. There was no significant regional difference in density of tau-positive neuronal inclusion when compared nucleus by nucleus, but the inclusions were most abundant in EnR in all subtypes Table 4) . Small amount of astrocytic inclusion (Fig. 3H) was found in FTLD-GRN and sFTLD/MND cases. Argyrophilic grain pathology was found in only 1 case of sFTLD/MND without amygdaloid TDP-43 pathology (Table 2) . Correlation between TDP-43 pathology and tau inclusion pathology could only be found in BLG-D (r s ¼ 0.631; n ¼ 19, p ¼ 0.004) ( Table 5 ).
There were no statistically significant differences of both TDP-43-and tau-positive inclusion densities between the sectional levels along the antero-posterior axis (Supplementary Data Fig. S1 ).
DISCUSSION
In this study, we compared the involvement of the amygdala with TDP-43-positive inclusions in sFTLD/MND, FTLD/MND-C9, and FTLD-GRN. The shapes of intracytoplasmic inclusions were similar in the 3 subtypes. In patients of sFTLD/MND and FTLD/MND-C9, the packing density of TDP-43-positive inclusions tended to be higher in the BLG-V. The neurites in the amygdala of patients were abundant in FTLD-GRN and few in those with sFTLD/MND or FTLD/ MND-C9. This profile was similar to the profile of cortical pathology previously reported in FTLD-TDP brains (4, 5) . In contrast, the distribution of the TDP-43-positive neuronal cytoplamic inclusions was focal in the cortex, involving predominantly layer II (FTLD-TDP Mackenzie type A) and diffuse in the amygdala in FTLD-GRN, whereas it was diffuse in the cortex (Mackenzie type B) and predominated in the BLG-V of the amygdala in our series of sFTLD/MND and FTLD/ MND-C9 (Table 5 ) (25) . These differences in distribution in the amygdala could correspond to the involvement of different systems of connections to and from the cortex or other areas. Indeed, TDP-43 pathology extended to the wide range of frontotemporal regions that have dense connections with amygdala (Supplementary Data Table S1 ). FTLD-GRN possibly relates to preferential involvement of amygdaloamygdaloid (interamygdaloid) and amygdalofugal system. BL and BM involved in FTLD-GRN are indeed major recipient of interamygdaloid projections and are major sources of amygdalofugal projections ( Fig. 1C ) (29, 30) . On the other hand, sporadic and C9-mutated FTLD/MND possibly relate to predominate in amygdaloid afferent systems; the amygdalopetal involvement from the deep layers of the cortex involved in sFTLD/MND and FTLD/MND-C9 (but not in FTLD-GRN) would explain the involvement of La or PL. Few connections from La also project to superficial cortical layer (30); however, they receive large amount of afferents from layer III and V of the cortices (Fig. 1C ) (31) (32) (33) (34) (35) . It is known that the neuronal loss would be associated with shrinkage of background structures and decreased number of inclusions. In the present study, numerical density of TDP-43-positive inclusions was strongly linked with glial density more than neuronal density in the amygdala (Supplementary Data Table S2 ). This would suggest that the increasing density of TDP-43 inclusions might be pathological and could not be simply explained by the shrinkage of background structures. However, in La or PAC, gliosis was present in spite of the low number of TDP-43-positive inclusions. La is a major area of BLG-V, which receives abundant projections from the other areas of the amygdala and from various cortical areas (Fig. 1C) (33) (34) (35) . PAC also receives abundant afferents fibers from the olfactory bulb and hippocampus (Fig. 1C) (32, 35, 36) . Gliosis could be the consequence of degeneration that would be secondary to the primary involvement of other areas, in the amygdala or in the cortex, with which La and PAC are abundantly connected.
Tau-positive neuronal inclusions (including NFTs) were significantly more abundant in FTLD-GRN than in sFTLD/ MND and FTLD/MND-C9 (Table 3 ). The tau inclusion pathology was probably correlated with age. However, recent study suggested that a reduction of granulin protein could enhance phosphorylation and intraneuronal accumulation of tau (37) . The tau accumulation, which was evident in FTLD-GRN in our series, was possibly enhanced by granulin reduction. When compared nucleus by nucleus, the correlative relationship between tau and TDP-43 accumulation was not observed except in BLG-D (Table 5) . Indeed, Robinson et al. reported no interaction between tau and TDP-43 accumulation in patients with FTLD (38) . We found small amounts of astrocytic inclusions most frequently in FTLD-GRN (Fig. 3H) . Further investigation of this astrocytic tau inclusion may contribute to clarification of relationship between tau and TDP-43 accumulation in FTLD/MND. Some recent reports revealed that argyrophilic grain pathology has a possible relationship with TDP-43 pathology (39) and prevalence of tau pathology has been found to be increased in C9ORF72 mutation patients (40) . We could not confirm this observation in the amygdala since argyrophilic grains were not found in any of the FTLD-TDP cases of this series.
Distinctive p62-positive/TDP-43-negative inclusions were previously found in cases with FTLD/MND-C9 in the hippocampus and cerebellar granular cells (12, 27, 28) . In our study, the densities of TDP-43-positive and p62-positive inclusions were similar in the amygdala of sFTLD/MND, FTLD/MND-C9, and FTLD-GRN and p62 pathology was not in excess in the amygdala of FTLD/MND-C9, unlike in the hippocampus and cerebellar granular cells.
Clinico-pathological correlation in amygdala pathology was still sparse. The BLG, that we have found frequently involved, has been reported to encode emotional events with reference to their particular sensory-specific features (41) . Involvement of this region may alter the way values are emotionally apprehended, an alteration that leads to dissocial or senseless behaviors (10, 11, 42) . The present study showed that TDP-43-positive inclusions were common in the PL, which is known to receive afferent fibers from the La and from the hippocampal formation (35, 43) . The major sources of hippocampal inputs to the amygdala are rostral part of the CA1 and the subiculum (36) . Those regions are preferentially involved in patients with FTLD/MND patients (44, 45) . Interestingly, lesions of the hippocampo-amygdaloid projections cause impairment of contextual fear learning (46) , which is regarded as one of the symptoms of FTD (47) . On the other hand, the CMG, especially PC and PAC, primarily receives olfactory information from the olfactory bulb (Fig. 1C) (48) . Olfactory disturbance have been reported in ALS patients (49) (50) (51) , and we recently identified in these patients a TDP-43 pathology along the olfactory pathway that could impair their odor perception (52, 53) . Further investigations would be needed to elucidate the direct relationship between this TDP-43 pathology and the odor impairments in ALS disease.
In the present study, we could not always sample the tissue from amygdala at the same level. Therefore, we performed an intergroup comparison of inclusion density between 3 sectional levels along the antero-posterior axis. The sectional analyses revealed that the inclusion density was not different between anterior, middle and posterior levels of amygdala. Indeed, in spite of previous anatomical research regarding amygdaloid projections, topographical differences of projections of each amygdaloid subnucleus along the anteroposterior axis remains to be established (33, 34, 54) . There is, however, heterogeneity between the distinct functional groups of the amygdaloid complex; it is possible that there would be heterogeneity in the antero-posterior axis.
In conclusion, we have shown that TDP-43-positive cytoplasmic inclusions were frequently found in the amygdala of pathologically and genetically confirmed cases of sFTLD/ MND, FTLD/MND-C9, and FTLD-GRN. TDP-43-positive inclusions were distributed unevenly in patients with sFTLD/ MND and FTLD/MND-C9 and homogeneously in patients with FTLD-GRN. The most severe lesions were found in the ventral region of the basolateral nuclear group in all 3 diseases. The diversity of amygdala lesions, in part explained by the mutations in different genes, should cause a variety of clinical symptoms, but how symptoms of emotional and olfactory disturbances can discriminate between these diseases remain to be explored. It should also be determined how early these symptoms occur and at which stage of the disease they can contribute to the diagnosis.
